Cargando…

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial

CONTEXT: Dulaglutide reduced major adverse cardiovascular events (MACE) in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. Its efficacy and safety in older vs younger patients have not been explicitly analyzed. OBJECTIVE: This work aimed to assess efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riddle, Matthew C, Gerstein, Hertzel C, Xavier, Denis, Cushman, William C, Leiter, Lawrence A, Raubenheimer, Peter J, Atisso, Charles M, Raha, Sohini, Varnado, Oralee J, Konig, Manige, Lakshmanan, Mark, Franek, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063250/ https://www.ncbi.nlm.nih.gov/pubmed/33537745 http://dx.doi.org/10.1210/clinem/dgab065

Ejemplares similares

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
por: Kwan, Anita Y.M., et al.
Publicado: (2022)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2023)

Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results
por: Pantalone, Kevin M., et al.
Publicado: (2020)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
por: Torre, Enrico, et al.
Publicado: (2020)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
por: Patel, Hiren, et al.
Publicado: (2019)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
por: Gerstein, Hertzel C., et al.
Publicado: (2022)

RP rewind
Publicado: (2020)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922
por: Riddle, Matthew C., et al.
Publicado: (2013)

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
por: Ferdinand, Keith C., et al.
Publicado: (2016)

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

Unwinding and Rewinding: Double Faces of Helicase?
por: Wu, Yuliang
Publicado: (2012)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Rewinding the waves: tracking underwater signals to their source
por: Kadri, Usama, et al.
Publicado: (2017)

Mistreatment in Residency: Intervening With the REWIND Communication Tool
por: Pang, Joyce, et al.
Publicado: (2022)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Levorphanol: Rewinding an Old, Bygone Multimodal Opioid Analgesic!
por: Nair, Abhijit S, et al.
Publicado: (2019)

The reconsolidation using rewind study (RETURN): trial protocol
por: Astill Wright, Laurence, et al.
Publicado: (2021)

Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial
por: Ramachandran, Ambady, et al.
Publicado: (2012)

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
por: Boustani, M. A., et al.
Publicado: (2016)

27 September 2013: Fast forward and rewind to our Origins
por: Antonella Del Rosso
Publicado: (2013)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

Influence of the Strap Rewind Height During a Conical Pulley Exercise
por: Sabido, Rafael, et al.
Publicado: (2020)

Homecoming: rewinding the reductive evolution of the chloroplast genome for increasing crop yields
por: Llorente, Briardo, et al.
Publicado: (2021)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
por: Boye, Kristina S., et al.
Publicado: (2019)

Rash, disseminated intravascular coagulation and legionella: Episode 10 and a rewind into the past
por: Thalanayar, Prashanth M., et al.
Publicado: (2015)

Rewinding the Molecular Clock: Looking at Pioneering Molecular Phylogenetics Experiments in the Light of Proteomics
por: Neely, Benjamin A., et al.
Publicado: (2021)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon
por: Thieu, Vivian T., et al.
Publicado: (2020)

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
por: Cefalu, William T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ifvbj1jbaqedc6n4guupj8jlvh